Richard Burr: “The answer is absolutely yes.”

I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.

I am concerned Ms. Kotagal lacks impartiality to interpret the law.

it is clearly apparent by listening to this debate, if Senator Sanders had been on the PEB board, the PEB board wouldn't be making a recommendation and the President wouldn't be behind it. But that is where we are, short of a breakthrough…

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.